Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

MannKind Corporation - Common Stock (NQ:MNKD)

5.420 -0.150 (-2.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
Via Stocktwits
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
Via Stocktwits
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’
Via Stocktwits
Tuesday's pre-market session: top gainers and losers
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
From Brodsky & Smith LLC
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
A Look Ahead: MannKind's Earnings Forecast
 
Via Benzinga
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension 
From MannKind
Via GlobeNewswire
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion. 
Via Stocktwits
Earnings Scheduled For May 8, 2025
 
Via Benzinga
MannKind's Earnings Outlook
 
Via Benzinga
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity. 
Via Benzinga
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals. 
Via Stocktwits
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q2 Revenue Rises 6%
Via The Motley Fool
Topics Intellectual Property World Trade
MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market
MannKind Corp (MNKD) missed Q2 2025 revenue and EPS estimates, causing a 3.8% pre-market drop. Despite the miss, strategic moves like Blackstone's $500M financing and product pipeline progress offer... 
Via Chartmill
Topics Earnings
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
From MannKind
Via GlobeNewswire
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
From MannKind
Via GlobeNewswire
Top 3 Health Care Stocks That May Rocket Higher This Quarter
 
Via Benzinga
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
From MannKind
Via GlobeNewswire
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
From MannKind
Via GlobeNewswire
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.